Breaking News Instant updates and real-time market news.

ASNA

Ascena Retail

$2.17

0.07 (3.33%)

, SNX

Synnex

$116.50

0.4 (0.34%)

17:35
09/25/17
09/25
17:35
09/25/17
17:35

On The Fly: After Hours Movers

UP AFTER EARNINGS: Ascena Retail (ASNA), up 12.9%... Synnex (SNX), up 9%... Red Hat (RHT), up 4.1%. ALSO HIGHER: Actua Corporation (ACTA), up 23.3% after it entered into separate agreements to sell three majority-owned businesses for an aggregate of $549M in cash... ProQR Therapeutics (PRQR), up 3.9% after it presented "positive" top-line results from a Phase 1b study of QR-010 in subjects with cystic fibrosis. LOWER: Genocea (GNCA), down 45.6% after it announced a strategic shift to immuno-oncology and the development of neoantigen cancer vaccines, as well as a 40% reduction to its headcount... Kadmon (KDMN), down 16.6% after it filed to sell common stock and warrants... QEP Resources (QEP), down 8.7% after it announced the closing of its Pinedale divestiture and noted larger production declines from certain pilot wells... TherapeuticsMD (TXMD), down 3.3% after it filed to sell 12.4M shares of common stock... Bioptix (BIOP), down 3.2% after it changed its state of incorporation to Nevada from Colorado... CoStar Group (CSGP), down 1.8% after it announced a $750M common stock offering.

ASNA

Ascena Retail

$2.17

0.07 (3.33%)

SNX

Synnex

$116.50

0.4 (0.34%)

RHT

Red Hat

$105.76

-0.54 (-0.51%)

ACTA

Actua

$12.25

-0.1 (-0.81%)

PRQR

ProQR Therapeutics

$6.45

0.25 (4.03%)

GNCA

Genocea

$5.33

0.04 (0.76%)

KDMN

Kadmon

$3.79

0.27 (7.67%)

QEP

QEP Resources

$8.88

0.51 (6.09%)

TXMD

TherapeuticsMD

$6.06

-0.11 (-1.78%)

BIOP

Riot Blockchain

$4.11

-0.16 (-3.75%)

CSGP

CoStar Group

$279.20

-1.62 (-0.58%)

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 27

    Sep

  • 16

    Oct

  • 17

    Oct

  • 03

    Nov

  • 26

    Sep

ASNA Ascena Retail
$2.17

0.07 (3.33%)

03/08/17
GUGG
03/08/17
INITIATION
GUGG
Neutral
Ascena Retail initiated with a Neutral at Guggenheim
03/07/17
SBSH
03/07/17
DOWNGRADE
Target $3
SBSH
Sell
Ascena Retail downgraded to Sell with $3 target at Citi
Citi analyst Paul Lejuez downgraded Ascena Retail to Sell from Neutral saying the company has too many concepts with too many stores in a world increasingly moving to e-commerce. Ascena is behind the curve on omnichannel investment, which is likely to be a continued drag on margins, Lejuez tells investors in a research note post the company's Q2 results. He cut his price target for the shares to $3 from $5.50.
08/15/17
08/15/17
NO CHANGE

FBR lowers Specialty Retail price targets ahead of Q2 reports
FBR Capital analyst Susan Anderson expects Specialty Retail earnings in Q2 to be overall in-line with consensus estimates, with a lighter top line and gross margin given the need to promote to drive traffic. The analyst views American Eagle (AEO) and L Brands (LB) as winners in the quarter. She upgraded American Eagle this morning to Buy. Anderson also lowered her price target for Neutral-rated Abercrombie & Fitch (ANF) to $11 from $13, for Neutral-rated Ascena Retail (ASNA) to $3 from $5, for Neutral-rated Foot Locker (FL) to $58 from $66, for Neutral-rated Francesca's to $10 from $13, for Neutral-rated Gap (GPS) to $25 from $28 and for Neutral-rated Urban Outfitters (URBN) to $16 from $24.
03/21/17
KEYB
03/21/17
DOWNGRADE
KEYB
Sector Weight
Ascena Retail downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Todd Thomas downgraded Ascena Retail to Sector Weight largely to reflect the prospects of further store closings.
SNX Synnex
$116.50

0.4 (0.34%)

09/18/17
NEED
09/18/17
INITIATION
NEED
Buy
Synnex coverage resumed with a Buy at Needham
Needham analyst Sean Hannan resumed coverage of Synnex with a $135 price target and a Buy rating. The analyst says that the company is benefiting from "healthy IT spending trends," including strong data center and cloud activity. He believes that its acquisition of Westcon-Comstor should boost its offering and geographic position. He calls the company "an attractive name possessing high-quality execution, a diversified business, and an improving model through strategic M&A. "
08/24/17
LOOP
08/24/17
INITIATION
Target $140
LOOP
Buy
SYNNEX initiated with a Buy at Loop Capital
Loop Capital analyst Ananda Baruah started SYNNEX with a Buy rating and $140 price target.
09/01/17
SBSH
09/01/17
NO CHANGE
Target $100
SBSH
Neutral
Tech Data price target lowered to $100 from $115 at Citi
Citi analyst Jim Suva explains why shares of Tech Data (TECD) dropped 20% on last night's disappointing earnings report. The cloud is gaining traction, allowing some vendors to shift products internally as well as less distributor rebates, which is resulting in increased competition and lower financial incentives, Suva tells investors in a post-earnings research note. He views Tech Data's earnings report as a negative for Sell-rated Arrow Electronics (ARW) and Avnet (AVT) as well as Neutral-rated Synnex (SNX), but a positive for HP Inc. (HPQ) and Apple (AAPL) as top line sales of PCs and smartphones are doing well. Suva cut his price target for Tech Data shares to $100 from $115 and keeps a Neutral rating on the name.
05/19/17
05/19/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Goldman Sachs analyst Brett Feldman added T-Mobile (TMUS) to the firm's Conviction Buy List and increased its price target to $81 from $74 based on potential capital returns and upside to subscriber growth forecasts. 2. Jefferies analyst John DiFucci upgraded Palo Alto Networks (PANW) to Buy and raised his price target for the shares to $150 from $130. Palo's recent operational weakness has more to do with a major product cycle than sales execution or increased competition, DiFucci tells investors. 3. Oppenheimer analyst Brian Nagel upgraded Lumber Liquidators (LL) to Outperform saying a "potentially prolonged recovery" is starting to take shape under new management. 4. Raymond James analyst Adam Tindle upgraded SYNNEX (SNX) two notches to Strong Buy from Market Perform and established a $122 price target on shares saying key metrics are "poised to inflect." 5. RBC Capital upgraded Autodesk (ADSK) to Outperform from Sector Perform. Analyst Matthew Hedberg says he has increased confidence in the transition of the company's business model after it reported stronger than expected Q1 results. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
RHT Red Hat
$105.76

-0.54 (-0.51%)

09/06/17
MOFT
09/06/17
INITIATION
Target $135
MOFT
Buy
Red Hat initiated with a Buy at MoffettNathanson
MoffettNathanson analyst Adam Holt initiated Red Hat with a Buy and a $135 price target.
09/05/17
09/05/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Owens-Illinois (OI) initiated with a Neutral at UBS. 2. Akamai (AKAM) initiated with a Neutral at Credit Suisse. 3. Zealand Pharma (ZEAL) was initiated with a Buy at Needham and Guggenheim while being initiated with an Overweight at Morgan Stanley. 4. YogaWorks (YOGA) was initiated with an Outperform at Cowen, an Overweight at Stephens, and a Buy at Roth Capital and Guggenheim. 5. Red Hat (RHT) initiated with a Neutral at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/08/17
KEYB
09/08/17
INITIATION
Target $121
KEYB
Overweight
Red Hat resumed with an Overweight at KeyBanc
KeyBanc analyst Alex Kurtz resumed coverage of Red Hat with an Overweight rating and $121 price target. The analyst believes the company's products continue to have a strong secular position.
09/13/17
JMPS
09/13/17
NO CHANGE
Target $122
JMPS
Outperform
Red Hat price target raised to $122 after open source event at JMP Securities
After attending the Open Source Summit North America, JMP Securities analyst Greg McDowell said open source is not only growing but accelerating "exponentially," adding that he believes Red Hat has been and should continue to be a beneficiary of the trend. Given that the summit left him feeling better about Red Hat's prospects, he raised his price target on the stock to $122 from $107. McDowell keeps an Outperform rating on Red Hat shares ahead of the company's earnings report on September 25.
ACTA Actua
$12.25

-0.1 (-0.81%)

PRQR ProQR Therapeutics
$6.45

0.25 (4.03%)

09/28/16
JANY
09/28/16
INITIATION
JANY
Neutral
ProQR Therapeutics initiated with a Neutral at Janney Capital
Janney Capital analyst Roy Buchanan initiated ProQR Therapeutics with a Neutral rating saying there is too much uncertainty ahead of important phase 2 data for its oligonucleotide candidate QR-010 in undefinedF508 cystic fibrosis in mid-October
GNCA Genocea
$5.33

0.04 (0.76%)

03/06/17
03/06/17
NO CHANGE

FBR sees 'prime' merger environment for biotechs under Trump
Potential tax reform and FDA policy changes under President Trump could "prime the pump" for acquisitions of clinical-stage biotech companies by Big Pharma, FBR Capital analysts led by Chris Meekins tell investors in a research note. These police moves, coupled with the repeal of some taxes associated with the Affordable Care Act, are likely to increase funds for companies looking to make acquisitions, the analysts contend. Within its coverage universe, FBR sees TESARO (TSRO), Agile Therapeutics (AGRX), Kite Pharma (KITE), Juno Therapeutics (JUNO), Acceleron Pharma (XLRN), Abeona Therapeutics (ABEO), Aurinia Pharmaceuticals (AUPH), Geron (GERN) and Genocea Biosciences (GNCA) as "primary targets for those looking to make acquisitions."
07/24/17
NEED
07/24/17
UPGRADE
NEED
Buy
Genocea upgraded to Buy from Hold at Needham
07/25/17
07/25/17
UPGRADE
Target $12

Buy
Genocea upgraded to Buy at Needham
As previously reported, Needham analyst Alan Carr upgraded Genocea to Buy from Hold, with a $12 price target, after the company announced data from GEN-003 Phase 2b trial in HSV2 demonstrating durable efficacy through 12 months, and as he believes there is a "feasible" independent path to market. The analyst thinks GEN-003 is likely to be differentiated and convenient option with public health benefits.
07/25/17
STFL
07/25/17
NO CHANGE
STFL
Genocea data positive, says Stifel
Stifel analyst Stephen D. Willey says that Phase 2b data showing that Genocea's f GEN-003 achieved its primary endpoint in treating genital herpes is positive. The analyst says any clarity into new funding for a Phase 3 development program "should help re-rate the stock to a valuation which more appropriately reflects the longer-term market opportunity." He keeps a $15 price target and a Buy rating on the stock.
KDMN Kadmon
$3.79

0.27 (7.67%)

03/16/17
WBBS
03/16/17
UPGRADE
WBBS
Hold
Kadmon upgraded to Hold from Sell at WBB Securities
WBB Securities analyst Stephen Brozak upgraded Kadmon to Hold.
03/14/17
PIPR
03/14/17
INITIATION
Target $7
PIPR
Overweight
Kadmon initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff started Kadmon Holdings with an Overweight rating and $7 price target.
07/11/17
PIPR
07/11/17
NO CHANGE
Target $7
PIPR
Overweight
Kadmon interim Phase II data 'impressive,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff views Kadmon's preliminary Phase II data for KD025 in graft versus host disease patients as "impressive." Safety was "clean" and the primary endpoint was met, Tenthoff tells investors in a research note. He reiterates an Overweight rating on the shares with a $7 price target.
08/02/17
PIPR
08/02/17
NO CHANGE
Target $7
PIPR
Overweight
Imbruvica approval in graft versus host positive for Kadmon, says Piper Jaffray
After the FDA expanded the approval of AbbVie (ABBV) and Johnson & Johnson's (JNJ) Imbruvica for the treatment of adults with chronic graft versus host disease, or cGVHD, Piper Jaffray analyst Edward Tenthoff said he views the news as positive for Kadmon's KD025. Imbruvica is tough for patients to tolerate, said Tenthoff, who sees an opportunity for KD025 to more safely treat cGVHD patients. He keeps an Overweight rating and $7 price target on Kadmon shares.
QEP QEP Resources
$8.88

0.51 (6.09%)

07/31/17
STFL
07/31/17
NO CHANGE
STFL
QEP Resources shares oversold, says Stifel
Stifel analyst Derrick Whitfield says that QEP is "oversold," creating a "compelling near-term trade opportunity." The analyst says that the "M&A overhang" on the stock has lifted, while its "value proposition has improved" and it no longer poses significant risk. He thinks that the stock reflects less than $40 per barrel oil, and his sum of the parts analysis indicates that the shares are undervalued by about 75%.
07/28/17
EVER
07/28/17
NO CHANGE
Target $12
EVER
In Line
QEP Resources added to Tactical Outperform List at Evercore ISI
Evercore ISI analyst Stephen Richardson added QEP Resources to the Tactical Outperform List primarily due to valuation and thinks relative value will be noticed by the market given its high quality undeveloped Permian acres. Richardson rates QEP an In Line with a $12 price target.
07/28/17
JPMS
07/28/17
DOWNGRADE
Target $9
JPMS
Neutral
QEP Resources downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Gabriel Daoud downgraded QEP Resources to Neutral and lowered his price target for the shares to $9 from $11.Williston performance continues to disappoint, which largely drove the 7% oil miss in Q2, the analyst tells investors in a research note.
07/27/17
JPMS
07/27/17
DOWNGRADE
JPMS
Neutral
QEP Resources downgraded to Neutral from Overweight at JPMorgan
TXMD TherapeuticsMD
$6.06

-0.11 (-1.78%)

09/15/17
CANT
09/15/17
NO CHANGE
Target $33
CANT
Overweight
TherapeuticsMD 'countdown has begun' with data submission, says Cantor
Cantor Fitzgerald analyst William Tanner says the "countdown has begun" for TherapeuticsMD's TX-004 now that the company disclosed additional endometrial safety data have been submitted to the FDA. He sees the shares being "range-bound in classic battleground stock fashion" ahead of the FDA's decision, barring provision of any additional information. Tanner has an Overweight rating on TherapeuticsMD with a $33 price target.
09/13/17
DBAB
09/13/17
NO CHANGE
Target $10
DBAB
Buy
Deutsche Bank positive on TherapeuticsMD's compounding switch potential
Deutsche Bank analyst Esther Rajavelu recently met with two compounding pharmacists to assess their ability and motivation to switch patients to TX-001, TherapeuticsMD's single pill combination for vasomotor symptoms in menopausal women. The analyst remains optimistic over "strong uptake in this patient segment." The company's opportunity from compounded hormone therapies to TX-001 remains underappreciated, Rajavelu tells investors in a research note. The analyst models launch in late 2018 with revenue reaching $1B in five years. Rajavelu reiterates a Buy rating on the shares with a $10 price target.
09/08/17
MSCO
09/08/17
INITIATION
Target $6
MSCO
Equal Weight
TherapeuticsMD initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Thomas Smith started TherapeuticsMD with an Equal Weight rating and $6 price target. He believes TX-001HR and TX-004HR are promising products. However, TX-004HR has regulatory uncertainty and he thinks consensus expectations for the product are overly optimistic.
09/07/17
JEFF
09/07/17
NO CHANGE
Target $15
JEFF
Buy
Jefferies say key opinion leader supportive of TherapeuticsMD's TX-004
TherapeuticsMD management last night participated in a conference call with Dr. Kaunitz, a co-author of the recently published National Institutes of Health paper on vaginal estrogen and safety observations from the Women's Health Initiative Observational Study, Jefferies analyst Matthew Andrews tells investors in a research note. Kaunitz believes the data reinforce the long-term safety of vaginal estrogen, and does not believe there is a safety signal for elevated endometrial cancers, the analyst adds. Andrews admits that there are limitations with the study. He has a Buy rating on TherapeuticsMD with a $15 price target.
BIOP Riot Blockchain
$4.11

-0.16 (-3.75%)

CSGP CoStar Group
$279.20

-1.62 (-0.58%)

09/13/17
RHCO
09/13/17
NO CHANGE
RHCO
CoStar Group acquisition positive, says SunTrust
SunTrust analyst Andrew W. Jeffrey, says that Costar's (CSGP) acquisition of ForRent " should enable CoStar to take share in the large and growing Multifamily marketplace." He adds that ForRent's sales force should enable Costar's bookings growth to accelerate, and he thinks its synergy guidance is "conservative." Jeffrey keeps a $310 price target and a Buy rating on CoStar.
07/28/17
SBSH
07/28/17
NO CHANGE
Target $320
SBSH
Buy
CoStar Group price target raised to $320 from $275 at Citi
Citi analyst Peter Christiansen raised his price target for CoStar Group to $320 saying Q2 marks the bottom ahead of multiple quarters of leverage gains. With CoStar Suite enjoying its best bookings, multifamily scaling rapidly and LoopNet monetization beginning to take hold, CoStar is on the path to experiencing re-rating of its earnings power, Christiansen tells investors in a research note. He keeps a Buy rating on the shares.
06/05/17
JMPS
06/05/17
NO CHANGE
JMPS
CoStar Group tone of business 'awesome', says JMP Securities
After meeting with CoStar's VP, IR, JMP Securities analyst Patrick Walravens says that the company's "tone of business" is "awesome," as the company "appears to be hitting on all cylinders." He raised his price target on the shares to $277 from $256 and keeps an Outperform rating on the stock.
07/05/17
RHCO
07/05/17
NO CHANGE
RHCO
CoStar Group price target raised to $310 from $275 at SunTrust
SunTrust analyst Andrew Jeffrey expects CoStar's organic revenue growth and EBITDA margin to accelerate, driven by its "proprietary data and lead-gen offerings, a significantly larger sales force, the benefits of aggressive marketing and likely 2018 LoopNet cross-sales." He raised his price target on the stock to $310 from $275 and keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

, SNY

Sanofi

$39.91

0.19 (0.48%)

08:32
02/19/18
02/19
08:32
02/19/18
08:32
Recommendations
AnaptysBio, Sanofi, Regeneron analyst commentary  »

AnaptysBio price target…

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

SNY

Sanofi

$39.91

0.19 (0.48%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 25

    Mar

  • 02

    May

  • 03

    May

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

08:26
02/19/18
02/19
08:26
02/19/18
08:26
Hot Stocks
AnaptysBio presents updated Phase 2 data for ANB020 in atopic dermatitis »

AnaptysBio announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

NWL

Newell Brands

$28.23

0.59 (2.13%)

08:20
02/19/18
02/19
08:20
02/19/18
08:20
Recommendations
Newell Brands analyst commentary  »

Newell Brands price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

AZN

AstraZeneca

$33.93

-0.09 (-0.26%)

08:17
02/19/18
02/19
08:17
02/19/18
08:17
Recommendations
AstraZeneca analyst commentary  »

AstraZeneca approval…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 23

    Apr

ABGLF

Acacia Mining

08:13
02/19/18
02/19
08:13
02/19/18
08:13
Upgrade
Acacia Mining rating change  »

Acacia Mining upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPAM

Epam Systems

$114.95

2.72 (2.42%)

08:08
02/19/18
02/19
08:08
02/19/18
08:08
Recommendations
Epam Systems analyst commentary  »

Epam Systems price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:05
02/19/18
02/19
08:05
02/19/18
08:05
General news
FX Update: The dollar has been trading on a firmer footing »

FX Update: The dollar…

GTES

Gates Industrial

$18.29

-0.09 (-0.49%)

08:05
02/19/18
02/19
08:05
02/19/18
08:05
Initiation
Gates Industrial initiated  »

Gates Industrial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$30.36

1.28 (4.40%)

08:03
02/19/18
02/19
08:03
02/19/18
08:03
Initiation
PagSeguro Digital initiated  »

PagSeguro Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAGS

PagSeguro Digital

$30.36

1.28 (4.40%)

08:02
02/19/18
02/19
08:02
02/19/18
08:02
Initiation
PagSeguro Digital initiated  »

PagSeguro Digital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTP

Midatech Pharma

$0.98

-0.0099 (-1.00%)

04:55
02/19/18
02/19
04:55
02/19/18
04:55
Conference/Events
Midatech Pharma management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

  • 27

    Feb

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/19/18
02/19
04:55
02/19/18
04:55
Conference/Events
American Academy of Dermatology holds annual meeting »

2018 AAD Annual Meeting…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 11

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 29

    Mar

  • 04

    Apr

  • 23

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 07

    Jun

  • 13

    Nov

03:05
02/19/18
02/19
03:05
02/19/18
03:05
General news
FX Update: The dollar traded generally firmer »

FX Update: The dollar…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

, ABBV

AbbVie

$118.60

3.7 (3.22%)

04:55
02/18/18
02/18
04:55
02/18/18
04:55
Conference/Events
American Academy of Dermatology holds annual meeting »

2018 AAD Annual Meeting…

ACRS

Aclaris Therapeutics

$20.13

-0.09 (-0.45%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

AGN

Allergan

$164.04

-0.43 (-0.26%)

ALIOF

Actelion

ARDX

Ardelyx

$5.80

-0.2 (-3.33%)

BVX

Bovie Medical

$2.50

0.1 (4.17%)

CELG

Celgene

$95.26

-0.88 (-0.92%)

CUTR

Cutera

$48.40

-2.1 (-4.16%)

HSIC

Henry Schein

$69.52

1.14 (1.67%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

LLY

Eli Lilly

$78.97

0.95 (1.22%)

LMNS

Lumenis

MYGN

Myriad Genetics

$32.81

-0.57 (-1.71%)

MYL

Mylan

$42.14

0.49 (1.18%)

NVS

Novartis

$86.91

0.23 (0.27%)

PFE

Pfizer

$36.26

0.55 (1.54%)

PG

Procter & Gamble

$82.60

0.19 (0.23%)

PRGO

Perrigo

$89.55

-0.1 (-0.11%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNY

Sanofi

$39.91

0.19 (0.48%)

UL

Unilever; also tag UN

$53.55

-0.22 (-0.41%)

UN

Unilever; also tag UL

$54.59

-0.15 (-0.27%)

WTKWY

Wolters Kluwer

$49.37

-0.27 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 21

    Feb

  • 26

    Feb

  • 27

    Feb

  • 02

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 12

    Mar

  • 12

    Mar

  • 25

    Mar

  • 29

    Mar

  • 04

    Apr

  • 23

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 17

    May

  • 30

    May

  • 13

    Nov

MRVL

Marvell

$22.68

-0.06 (-0.26%)

, CAVM

Cavium

$87.16

-0.09 (-0.10%)

14:55
02/17/18
02/17
14:55
02/17/18
14:55
Conference/Events
Cavium to host special shareholder meeting »

Special Shareholder…

MRVL

Marvell

$22.68

-0.06 (-0.26%)

CAVM

Cavium

$87.16

-0.09 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 20

    Feb

  • 08

    Mar

CAVM

Cavium

$87.16

-0.09 (-0.10%)

, MRVL

Marvell

$22.68

-0.06 (-0.26%)

14:51
02/17/18
02/17
14:51
02/17/18
14:51
Conference/Events
Marvell to host special shareholder meeting »

Special Shareholder…

CAVM

Cavium

$87.16

-0.09 (-0.10%)

MRVL

Marvell

$22.68

-0.06 (-0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

DEL

Deltic Timber

$98.45

1.77 (1.83%)

, PCH

Potlatch

$54.75

0.75 (1.39%)

14:45
02/17/18
02/17
14:45
02/17/18
14:45
Conference/Events
Potlatch to host special shareholder meeting »

Special Shareholder…

DEL

Deltic Timber

$98.45

1.77 (1.83%)

PCH

Potlatch

$54.75

0.75 (1.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

PCH

Potlatch

$54.75

0.75 (1.39%)

, DEL

Deltic Timber

$98.45

1.77 (1.83%)

14:42
02/17/18
02/17
14:42
02/17/18
14:42
Conference/Events
Deltic Timber to host special shareholder meeting »

Special shareholder…

PCH

Potlatch

$54.75

0.75 (1.39%)

DEL

Deltic Timber

$98.45

1.77 (1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$20.42

0.67 (3.39%)

09:31
02/17/18
02/17
09:31
02/17/18
09:31
Periodicals
Snap CEO sold $50M in stock this week, Recode reports »

Snap CEO Evan Spiegel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 07

    Mar

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

, MPSYY

MorphoSys

$46.29

1.29 (2.87%)

09:27
02/17/18
02/17
09:27
02/17/18
09:27
Hot Stocks
Galapagos NV, MorphoSys present results from Phase 1 study with MOR106 in AD »

Galapagos NV (GLPG) and…

GLPG

Galapagos NV

$115.33

-1.4 (-1.20%)

MPSYY

MorphoSys

$46.29

1.29 (2.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$360.53

-0.47 (-0.13%)

09:22
02/17/18
02/17
09:22
02/17/18
09:22
Hot Stocks
Lockheed Martin receives Freedom-variant FFG conceptual design contract »

The U.S. Navy awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 07

    Mar

  • 30

    May

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

, UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

09:11
02/17/18
02/17
09:11
02/17/18
09:11
Periodicals
Bears, bulls battle over Under Armour, Barron's says »

In a follow-up story,…

UAA

Under Armour; also tag UA

$17.36

-1.05 (-5.70%)

UA

Under Armour; also tag UAA

$15.78

-0.76 (-4.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOV

Hovnanian

$2.24

0.12 (5.66%)

09:04
02/17/18
02/17
09:04
02/17/18
09:04
Periodicals
Hovnanian stock too cheap to ignore, Barron's says »

Hovnanian Enterprises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

, JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

09:00
02/17/18
02/17
09:00
02/17/18
09:00
Periodicals
JPMorgan, Walmart cash flow yields exceed dividend yields, Barron's says »

The cash flow yields of…

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

WMT

Walmart

$104.78

1.55 (1.50%)

PFE

Pfizer

$36.26

0.55 (1.54%)

CSCO

Cisco

$44.33

0.25 (0.57%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

PEP

PepsiCo

$111.06

0.09 (0.08%)

MMM

3M

$236.67

1.8 (0.77%)

BMY

Bristol-Myers

$68.96

-0.02 (-0.03%)

UTX

United Technologies

$129.26

-0.74 (-0.57%)

TXN

Texas Instruments

$104.47

-0.1 (-0.10%)

ABT

Abbott

$60.17

0.67 (1.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Feb

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 23

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 13

    Mar

  • 29

    Mar

  • 04

    Apr

  • 13

    Apr

  • 30

    May

  • 14

    Jul

  • 12

    Oct

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

, GOOG

Alphabet

$1,094.80

5.28 (0.48%)

08:56
02/17/18
02/17
08:56
02/17/18
08:56
Periodicals
Alphabet, Citi well positioned for later stages of market rally, Barron's says »

It is time for investors…

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

GOOG

Alphabet

$1,094.80

5.28 (0.48%)

C

Citi

$76.82

-0.26 (-0.34%)

CMI

Cummins

$165.60

0.58 (0.35%)

LRCX

Lam Research

$187.91

2.2 (1.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 18

    Mar

  • 28

    Mar

  • 29

    Mar

  • 30

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.